Warfarin/Yeni Nesil Oral Antikoagülan ve K-Vitamini Zehirlenmeleri

Zapata LV, Hansten PD, Panic J, et al. Risk of Bleeding with Exposure to Warfarin and Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review and Meta-Analysis. Thrombosis and haemostasis. 2020; 120 (7): 1066.

Hu TY, Vaidya VR, and Asirvatham SJ. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vascular health and risk management. 2016; 12: 35–44.

Vu TT, and Gooderham M. Adverse drug reactions and cutaneous manifestations associated with anticoagulation. Journal of Cutaneous Medicine and Surgery. 2017; 1(6):540-550.

Baker RI, Coughlin PB, Gallus AS et al. The Warfarin Reversal Consensus Group Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Medical Journal of Australia. 2004; 181(9):494-497.

Kumar R, Smith RE, and Henry BL. A review of and recommendations for the management of patients with life-threatening dabigatran-associated hemorrhage: a single-center university hospital experience. Journal of intensive care medicine. 2015; 30(8): 462-472.

Chiew AL, Khamoudes D, and Chan BSH. Use of continuous veno-venous haemodiafiltration therapy in dabigatran overdose. Clinical toxicology. 2014; 52(4):283-287.

Wood P. New oral anticoagulants: an emergency department overview. Emergency Medicine Australasia.2013; 25(6):503-514.

Siegal DM, Curnutte JT, Conolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. New England Journal of Medicine. 2015; 373(25):2413-2424.

Rasmussen, SE,Andersen NL, Dragsted LO, et al. A safe strategy for addition of vitamins and minerals to foods. European Journal of Nutrition. 2006; 45(3):123-135.